Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Development programs currently in clinical studies by Quarter
Development programs currently in clinical studies (programs)
Moderna Development programs currently in clinical studies: 36.00 programs in Q2 2026, up 2.9% from a year earlier.
Latest, Q2 2026
36.00
Period ended Jun 30, 2026
Change on a year earlier
+2.9%
35.00 in Q2 2025
History
28 quarters
Since Q4 2018
Sources
28
Documents cited below
Where the Q2 2026 figure comes from
“Additionally, we have a diverse development pipeline of 26 development candidates across our 36 development programs currently in clinical studies.”
Source: Q2 2026 10-Q ↗
Reported in Form 10-Q / 10-K Note 1, MD&A & Form 8-K Earnings Releases.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development programs currently in clinical studies (programs) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 36.00 | +2.9% | Q2 2026 10-Q ↗ |
| Q1 2026 | Mar 31, 2026 | 35.00 | -7.9% | Q1 2026 10-Q ↗ |
| Q4 2025 | Dec 31, 2025 | 35.00 | -14.6% | FY2025 10-K ↗ |
| Q3 2025 | Sep 30, 2025 | 37.00 | -11.9% | Q3 2025 10-Q ↗ |
| Q2 2025 | Jun 30, 2025 | 35.00 | -18.6% | Q2 2025 10-Q ↗ |
| Q1 2025 | Mar 31, 2025 | 38.00 | -11.6% | Q1 2025 10-Q ↗ |
| Q4 2024 | Dec 31, 2024 | 41.00 | +2.5% | FY2024 10-K ↗ |
| Q3 2024 | Sep 30, 2024 | 42.00 | +10.5% | Q3 2024 10-Q ↗ |
| Q2 2024 | Jun 30, 2024 | 43.00 | +10.3% | Q2 2024 10-Q ↗ |
| Q1 2024 | Mar 31, 2024 | 43.00 | +19.4% | Q1 2024 10-Q ↗ |
| Q4 2023 | Dec 31, 2023 | 40.00 | +5.3% | FY2023 10-K ↗ |
| Q3 2023 | Sep 30, 2023 | 38.00 | +8.6% | Q3 2023 10-Q ↗ |
| Q2 2023 | Jun 30, 2023 | 39.00 | +25.8% | Q2 2023 10-Q ↗ |
| Q1 2023 | Mar 31, 2023 | 36.00 | +24.1% | Q1 2023 10-Q ↗ |
| Q4 2022 | Dec 31, 2022 | 38.00 | +52.0% | Q4 2022 Earnings Release (8-K) ↗ |
| Q3 2022 | Sep 30, 2022 | 35.00 | +66.7% | Q3 2022 Earnings Release (8-K) ↗ |
| Q2 2022 | Jun 30, 2022 | 31.00 | – | Q2 2022 Earnings Release (8-K) ↗ |
| Q1 2022 | Mar 31, 2022 | 29.00 | – | Q1 2022 Earnings Release (8-K) ↗ |
| Q4 2021 | Dec 31, 2021 | 25.00 | – | Q4 2021 Earnings Release (8-K) ↗ |
| Q3 2021 | Sep 30, 2021 | 21.00 | +61.5% | Q3 2021 Earnings Release (8-K) ↗ |
| Q3 2020 | Sep 30, 2020 | 13.00 | 0.0% | Q3 2020 Earnings Release (8-K) ↗ |
| Q2 2020 | Jun 30, 2020 | 13.00 | 0.0% | Q2 2020 Earnings Release (8-K) ↗ |
| Q1 2020 | Mar 31, 2020 | 13.00 | +18.2% | Q1 2020 Earnings Release (8-K) ↗ |
| Q4 2019 | Dec 31, 2019 | 12.00 | +9.1% | FY2019 10-K ↗ |
| Q3 2019 | Sep 30, 2019 | 13.00 | – | Q3 2019 10-Q ↗ |
| Q2 2019 | Jun 30, 2019 | 13.00 | – | Q2 2019 10-Q ↗ |
| Q1 2019 | Mar 31, 2019 | 11.00 | – | Q1 2019 10-Q ↗ |
| Q4 2018 | Dec 31, 2018 | 11.00 | – | FY2018 10-K ↗ |
Cite this data
StockData. (2026). Moderna Development programs currently in clinical studies, quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/pipeline-clinical
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.